Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-07-15
2008-07-15
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S325000
Reexamination Certificate
active
10832777
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
REFERENCES:
patent: 5563036 (1996-10-01), Peterson et al.
patent: 5652222 (1997-07-01), Calabretta et al.
patent: 5693463 (1997-12-01), Edwards et al.
patent: 5708158 (1998-01-01), Hoey
patent: 5716780 (1998-02-01), Edwards et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5770445 (1998-06-01), Kindsvogel et al.
patent: 5776725 (1998-07-01), Kindsvogel et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5804383 (1998-09-01), Gruenert et al.
patent: 5919635 (1999-07-01), Kindsvogel et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6251873 (2001-06-01), Furusako et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6770486 (2004-08-01), Griffey et al.
patent: 2003/0087856 (2003-05-01), Bennett et al.
patent: 2003/0144242 (2003-07-01), Ward et al.
patent: 2004/0016030 (2004-01-01), Lowe et al.
patent: 2005/0014713 (2005-01-01), Freier et al.
patent: 2005/0074801 (2005-04-01), Monia et al.
patent: 2005/0142581 (2005-06-01), Griffey et al.
patent: 2006/0063730 (2006-03-01), Monia et al.
patent: 2007/0087987 (2007-04-01), Monia et al.
patent: WO94/05789 (1994-03-01), None
patent: WO 94/05789 (1994-03-01), None
patent: WO 00/05418 (2000-03-01), None
patent: WO2002/045494 (2002-06-01), None
patent: WO 2002/045494 (2002-06-01), None
patent: WO 2004/096016 (2004-11-01), None
patent: WO 2004/096996 (2004-11-01), None
patent: WO 2005/023995 (2005-03-01), None
patent: WO 2006/34348 (2006-03-01), None
patent: WO 2007/035771 (2007-03-01), None
Chambers et al.,Glucagon Receptor Gene Mutation In Essential Hypertension, Molecular Biology & Hypertension Laboratory, Nature Genetics, vol. 12, p. 122, Feb. 1996.
Fujisawa, T.,A Mutation in the Glucagon Receptor Gene(Gly40Ser):Heterogeneity in the Association with Diabetes Mellitus, Diabetologia, pp. 983-985, Apr. 1995.
Liang, Yin,Reduce Glucocorticoid Receptor Expression in Liver Amellorates Diabetic Syndrome in ob/ob and db/db Mice, Clinical Therapeutics/New Technolgoy-Pharmacologic Treatment of Diabetes or its Complications, p. A134, Article 566-P.
Lok, Si,The Human Glucagon Receptor Encoding Gene: Structure, cDNA Sequence and Chromosomal Localization, Elsevier Science B.V., pp. 203-209, 1994.
MacNeil, Douglas J.,Cloning and Expression of a Human Glucagon Receptor, Biochemical and Biophyscial Research Communications, vol. 198, No. 1, pp. 328-334, Jan. 1994.
Madsen, P.,Advances in Non-Peptide Glucagon Receptor Antagonists, Bentham Science Publishers B.V., pp. 683-691, 1999.
Siani, Alfonso,Gly40Ser Polymorphism of the Glucagon Receptor Gene is Associated with Central Adiposity in Men, Obesity Research, vol. 9, No. 11, pp. 722-726, Nov. 2001.
Link, J. T., “Pharmacological regulation of hepatic glucose production,”Curr. Opin. Invest. Drugs(2003) 4(4):421-429.
PCT International Search Report for PCT/US04/13120 dated Jun. 27, 2005.
Liang, Yin, et al., “Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome indb/dbMice,”Diabetes, 53: 410-417 (2004).
Database Genseq (online) Jan. 7, 2002, “Human Stat3 Amplifying RT-PCR Primer #2,” Ref. WPI; 2002-034368/04. XP-002404609, Database accession No. AAD24334.
Database Genseq (online) Jan. 21, 1998, “Nucleotide Sequence of the RT-PCR Primer A,” Ref. WPI; 1998-531578/45. XP-002404610, Database accession No. AAV60964.
Database Genseq (online) Jan. 16, 2004, “Novel Mutant Protein Tyrosine Kinase-Related Oligonucleotide SeqID985,” Ref. WPI; 2004-718702/70. XP-002404611, Database accession No. ADT00997.
Database Genseq (online) Jan. 27, 2005, “Knock-Down Target Sequence #7049,” Ref. WPI; 2004-775940/76. XP-002404612, Databse accession No. ADU41870.
Database Genseq (online) Jan. 27, 1999, “Oligonucleotide Derived From Pinene Synthase,” Ref. WPI; 1999-120396/10. XP-002404613, Database accession No. AAX08680.
Database Genseq (online) Jan. 5, 2002, “Human Polymorphism Associated DNA Sequence #415,” Ref. WPI; 2002-619265/66. XP-002404614, Database accession No. ABS60778.
Database Genseq (online) Jan. 30, 2000, “Hepatitis GB Virus PCR Primer SEQ ID No. 648,” Ref. WPI; 2000-338307/29. XP-002404615, Database accession No. AAA55422.
Database Genseq (online) Jan. 3, 1994, “Human Glucagon Receptor Primer ZC5432,” Ref. WPI; 1994-101194/12. XP-002404616, Database accession No. AAQ58770.
Database Genseq (online) Jan. 20, 2002, “Human KTOM1a Portion (ABQ63232) Probe #137,” Ref. WPI; 2002-479509/51. XP-002404617, Database accession No. ABQ63424.
Database Genseq (online) Jan. 20, 2002, “Oligonucleotide SEQ ID No. 21800 for Detecting SNP TSC0004359,” Ref. WPI; 2001-657177/75. XP-002404618, Database accession No. ABC21783.
Database Genseq (online) Jan. 20, 2002, “DNA Oligonucleotide Sequence #5,” Ref. WPI; 2002-088875/12. XP-002404712, Database accession No. ABA92515.
Database EM-PAT, Oct. 6, 1999. XP-002404619, retrieved from EBI. Database accession No. AR065230, abstract.
Database EM-PAT, Aug. 12, 2002, “Sequence 913 from patent WO0224750.” XP-002404620, Database accession No. AX475692.
Database Genseq (online) Jan. 25, 2001, “Human IL4 Gene PCR Primer SEQ ID No. 78,” Ref. WPI; 2001-316132/33. XP-002404621, Database accession No. AAH18819.
Agrawal et al., “Antisense therapeutics: Is it as simple as complementary base recognition?” Mol. Med. Today: Reviews 61:72-81 (2000).
Crooke et al., “Progress in antisense technology,” Annu. Rev. Med. 55:61-95 (2004).
Jen et al., “Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies,” Stem Cells, 18:307-319 (2000).
Opalinska et al., “Nucleic acid therapeutics: basic principles and recent applications,” Nature Reviews: Drug Discovery 1:503-514 (2002).
Taylor et al, “Antisense oligonucleotides: a systematic high-throughput approach to target a validation and gene function determination,” DDT vol. 4, No. 12, Dec. 1999.
Chambers, S.M. et al., “Glucagon Receptor Gene Mutation in Essential Hypertension,” Molecular Biology & Hypertension Laboratory,Nature Genetics, (1996)12:122.
Fujisawa, T. et al., “A Mutation in the Glucagon Receptor Gene (Gly40Ser): Heterogeneity in the Association with diabetes Mellitus,”Diabetologia, (1995) 38:983-985.
Liang, Y. et al., “Reduce Glucocorticoid Receptor Expression in Liver Amellorates Diabetic Syndrome in ob/ob and db/db Mice,”Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its complications, (2003) p. A134, Article 566-P.
Lok, S. et al., “The Human Glucagon Receptor Encoding Gene: Structure, cDNA Sequence and Chromosomal Localization,”Elsevier Science B.V., (1994) 140:203-209.
MacNeil, D.J. et al., “Cloning and Expression of a Human Glucagon Receptor,”Biochemical and Biophysical Research Communications, (1994) 198(1):328-334.
Madsen, P. et al., “Advances in Non-Peptide Glucagon Receptor Antagonists,”Bentham Science Publishers B.V., (1999) 5:683-691.
Siani, A. et al., “Gly40Ser Polymorphism of the Glucagon Receptor Gene is Associated with Central Adiposty in Men,”Obesity Research, (2001) 9(11):722-726.
Bhanot Sanjay
Dobie Kenneth W.
Freier Susan M.
McKay Robert
Butzel Long
Chong Kimberly
ISIS Pharmaceuticals
McGarry Sean
LandOfFree
Modulation of glucagon receptor expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of glucagon receptor expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of glucagon receptor expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3914482